Shanghai Geno Biotech Co., Ltd.

Geno Biotech is a pioneer in non-invasive tumor diagnostic technology in the field of precision medicine, and a biotech company that has successfully developed a lung cancer liquid biopsy diagnostic product. Geno's affiliated companies are involved in multiple businesses including R&D, production, sales, and clinical testing services of tumor diagnostic products. Since its establishment in Zhangjiang, Shanghai in November 2010, Geno Biotech has received support from various national ministries and local governments for several important projects. Currently, Geno Biotech has been recognized as a high-tech enterprise domestically, and its liquid biopsy technology has been awarded multiple domestic and international recognitions for technological achievements, outstanding achievements, and academic contributions. While independently developing innovative technologies, Geno Biotech actively collaborates with world-renowned research and clinical institutions, including the Mayo Clinic, UCLA School of Medicine, Cancer Hospital of the Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Shanghai Pulmonary Hospital, and West China Hospital, to jointly promote the clinical application of the technology. Since 2013, relevant clinical research results have been published more than 10 times in internationally renowned oncology journals and have been reported at major international oncology conferences such as ASCO, WCLC, and CSCO. Tumors change rapidly and evolve under drug treatment pressure. Geno's self-developed and produced Folate Receptor Positive Circulating Tumor Cell Detection Kit obtained the Class III registration certificate approved by the National Medical Products Administration in January 2016. Its detection performance has been validated by large-scale clinical data, providing reliable evidence for precision cancer treatment, helping patients prolong survival, and improving the quality of life for every patient fighting the disease.